Latest News and Press Releases

-- First study to provide a head-to-head comparison of two commercially available supplements with regard to the changes in serum levels of carotenoids, visual function and macular pigment optical...

San Diego, California, March 06, 2020 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI), an ocular health sciences company that develops, formulates,...

 Formulation will be First Nutraceutical Compound to be Introduced Under Guardion’s Recently Acquired NutriGuard Business Line San Diego, California, Feb. 06, 2020 (GLOBE NEWSWIRE) --...

 Study Results Show 40 Times Higher Blood Concentration Levels of Mesozeaxanthin From Lumega-Z, Guardion’s Flagship Medical Food, as compared to Standard AREDS2 Over-The-Counter Gel Caps San Diego,...

San Diego, CA, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI), announced the pricing of an underwritten public offering of 13,000,000...

Highlights Include:  18.2% Revenue Growth for the Three Months Ended June 30, 2019 and 21.7% Revenue Growth for the Six Months Ended June 30, 2019 San Diego, CA , Aug. 12, 2019 (GLOBE...

The CSV-1000 Diagnostic Instrument is Considered the Standard of Care for the Measurement of Contrast Sensitivity San Diego, CA, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc....

San Diego, CA, July 17, 2019 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI), announced that it has received a patent from the Patents Registry in...

San Diego, CA, June 20, 2019 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI), an ocular health sciences and technologies company that develops,...

In an IRB-approved trial conducted at the New York Eye and Ear Infirmary, the parent compound of GlaucoCetin, GlaucoHealth, designed by Robert Ritch, MD, successfully reversed mitochondrial...